H.B. Fuller (FUL) Could Be 27% Undervalued After Its $850m Debt Raise

H.B. Fuller (FUL) just tapped the debt markets by issuing US$850m of 7.625% senior unsecured notes due 2034, a move closely linked to funding its planned Advanced Medical Solutions Group acquisition.

Those fresh notes land at a time when H.B. Fuller's share price has been under pressure, with the stock down 10.93% over the past 90 days and 17.78% year to date, while the 1 year total shareholder return has declined 17.94%. This points to fading momentum even as recent earnings and the AMS deal push a more ambitious growth and balance sheet reshaping story.

Spot under-pressure compounders like H.B. Fuller and compare them with our hand picked 27 high quality undervalued stocks that also pair earnings power with balance sheet strength.

H.B. Fuller has just taken on higher coupon debt, the share price has slid, yet earnings guidance has moved up. Does that shift the risk reward scale toward buyers or toward more caution on valuation?

Most Popular Narrative: 27% Undervalued

Against H.B. Fuller's last close at $49.61, the most followed narrative pegs fair value around $68.29, framing the recent share price slide in the context of a higher long term earnings outlook and the expansion of its medical adhesives business.

The acquisition of ND Industries and restructuring benefits are now joined by the pending AMS acquisition and the performance of prior medical deals such as GEM and Medifill. The enlarged medical platform is expected to reach roughly 10% of revenue and support EBITDA margins above 30% in that segment by 2030, which would contribute to higher consolidated revenue, margins and earnings.

See why 2 investors see H.B. Fuller as 27% undervalued .

Result: Fair Value of $68.29 (UNDERVALUED)

Still, this narrative breaks if AMS integration drags on or if higher petrochemical and raw material costs outpace H.B. Fuller's ability to preserve pricing power.

Find out about the key risks to this H.B. Fuller narrative .

Next Steps

Mixed messages around H.B. Fuller can leave you torn, so move quickly, review the data for yourself, and weigh both sides of the story with 6 key rewards and 1 important warning sign

Looking for more investment ideas beyond H.B. Fuller?

Do not stop at H.B. Fuller. Consider broadening your watchlist with a few targeted stock ideas that align with different risk levels, income needs, and balance sheet preferences.

• Target punchy opportunities in smaller companies that still show financial strength by scanning our 7 elite penny stocks with strong financials .

• Hunt for potential value by using the 27 high quality undervalued stocks that already blend solid financial quality with attractive pricing signals.

• Prioritise resilience by focusing on companies with stronger finances through our curated list of solid balance sheet and fundamentals (25 results) .